



ASX ANNOUNCEMENT

6 December 2021

Cann receives \$2.186 million R&D tax rebate

6 December 2021 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce it has received a \$2.186 million R&D Tax Incentive Rebate for the 2021 financial year.

The rebate relates to eligible R&D activities conducted by Cann, including its in-house research and those activities conducted through its strategic partnerships with key research partners.

The Australian Government's R&D Tax Incentive program provides companies with a tax offset for eligible R&D activities. The funds received will be reinvested into the continued development of Cann's end-to-end capabilities of cultivating and manufacturing GMP grade medicinal cannabis products.

"Cann knows that a key part of our growth is to continue to invest in our research and development programs, and the R&D tax incentive program is critical to enable such investment. With the Mildura facility nearing completion, the Company's investment in and continued development of the Satipharm technology, and with the upcoming clinical trial to support Cann's S3 registration application, we continue to focus on these R&D programs as a cornerstone of delivering results to patients and our shareholders," said Cann Group CEO Peter Crock.

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com